JP2000506894A - 中枢神経系の虚血または外傷の機能的回復を増大させる方法 - Google Patents
中枢神経系の虚血または外傷の機能的回復を増大させる方法Info
- Publication number
- JP2000506894A JP2000506894A JP9533583A JP53358397A JP2000506894A JP 2000506894 A JP2000506894 A JP 2000506894A JP 9533583 A JP9533583 A JP 9533583A JP 53358397 A JP53358397 A JP 53358397A JP 2000506894 A JP2000506894 A JP 2000506894A
- Authority
- JP
- Japan
- Prior art keywords
- morphogen
- bmp
- residue
- xaa
- nervous system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.下記の工程からなる、哺乳動物において中枢神経系の機能回復を増大させる 方法 虚血あるいは外傷を受けた中枢神経系傷害を有する哺乳動物にモルフォゲン の有効量を投与する、 ここで前記モルフォゲンは前記哺乳類において組織特異的形態形成を誘導する性 質をもつ2量体蛋白質からなる、そして1対のフォールドしたポリペプチドから なる、 各ペプチドはヒトOP−1のC−末端7システインドメイン、SEQID番号5 の残基38−139と少なくとも70%のホモロジーをもっているアミノ酸配列 を有する 2.前記機能回復が運動協調機能、感覚受容そして会話から選択される中枢神経 系機能の改善からなる請求項1の方法。 3.前記運動協調機能が姿勢、バランス、握力、歩行からなる請求項2の方法 4.ここで前記感覚受容が、視覚、聴覚、触覚、味覚、自己受容、臭覚からなる 請求項2の方法。 5.前記哺乳動物がヒトである請求項1の方法。 6.モルフォゲンの有効量が単回投与によって提供される請求項1の方法。 7.モルフォゲンの有効量が複数回の投与によって提供される請求項1の方法。 8.モルフォゲンの有効量が2回の投与によって提供される請求項6の方法。 9.ここでモルフォゲンの有効量が前記外傷後少なくとも6時間後に投与される 請求項1,6,7または8の方法。 10.ここでモルフォゲンの有効量が前記傷害後から少なくとも24時間で投与 される請求項1,6,7、または8の方法。 11.モルフォゲンの有効量が前記傷害後少なくとも48時間に投与される請求 項1,6,7、または8の方法。 12.モルフォゲンが毎日投与される請求項7の方法。 13.モルフォゲンが1週2回投与される請求項7の方法。 14.モルフォゲンが週毎に投与される請求項7の方法。 15.哺乳動物において中枢神経系の機能回復を増大させる方法であって下記の 工程からなる方法: 虚血あるいは外傷から選択される中枢神経系傷害をもった哺乳動物に有効量のモ ルフォゲンを投与する、 前記モルフォゲンは前記哺乳動物に組織特異的形態形成を誘導できる性質をもっ ている2量体蛋白質からなり、かつ1対の折り畳まれたされたポリペプチドから なる、2量体タンパク質とポリペプチドは下記からなる群から選択したアミノ酸 配列をもっている、 (a)SEQID番号1によって規定される遺伝子配列7 (b)SEQID番号2によって規定される遺伝子配列8 (c)SEQID番号6によって規定される遺伝子配列9 (d)SEQID番号7によって規定される遺伝子配列10 16.ここで前記アミノ酸配列が下記群から選ばれる請求項1または15の方法 、 (a)SEQID番号5の残基38−139、ヒトOP-1のC末端の7システイン ドメインと60%以上のアミノ酸配列の同一性をもつ配列、(b)SEQID番号 3によって規定されるOPX配列。 17.前記アミノ酸配列が、SEQID番号5の残基38−139ヒトOP−1 のC−末端7個のシステインドメインをもったものまたはそれらの保存的置換変 異体である請求項1または15の方法。 18.前記アミノ酸配列が、SEQID番号5の残基38−139、ヒトOP− 1のC−末端7個のシステインドメインをもったもの、またはそれらの自然に起 きた変異体のである請求項1または15の方法。 19.下記工程からなる哺乳動物において中枢神経系の機能の回復を増大させる 方法、 虚血あるいは外傷から選択される中枢神経系傷害をもった哺乳動物にモルフォゲ ンの有効量を投与する、 ここで前記モルフォゲンはヒトOP−1、マウスOP−1、ヒトOP−2、マウ スOP−2、60A、GDF−1、BMF−2A、BMF−2B,DPP,Vg 1、Vgr−1,BMP−3,BMP−5そしてBMP−6からなる群から選択 される。 20.下記工程からなる哺乳動物において中枢神経系の機能の回復を増大させる 方法、 虚血あるいは外傷から選択される中枢神経系傷害をもった哺乳動物にモルフォゲ ンの有効量を投与する、 ここで前記モルフォゲンはヒトOP−1、マウスOP−1、ヒトOP−2、マウ スOP−2、60A、GDF−1、BMF−2A、BMF−2B、DPP,Vg l、Vgr−1,BMP−3,BMP−5そしてBMP−6からなる群から選択 されるモルフォゲンの保存的置換変異体である。 21.前記モルフォゲンが、OP−1,OP−2,60A、GDF−1,BMP −2A、BMP−2B、DPP,Vgl、Vgr−1,BMP−3,BMP−5 そしてBMP−6のプロドメインのN末端からなる群から選択されたN−末端1 8アミノ酸ペプチドからなる少なくとも1個のプロドメインペプチドと複合体を つくる請求項1,6,7,8,15,19または20の方法。 22.前記モルフォゲンが、OP−1,OP−2,60A、GDF−1,BMP −2A、BMP−2B、DPP,Vgl、Vgr−l,BMP−3,BMP−5 そしてBMP−6のプロドメインからなる群から選択されたプロドメインポリペ プチドの保存的置換変異体である少なくとも1個のプロドメインポリペプチドと 複合体をつくる請求項1,6,7,8,15,19または20の方法。 23.前記モルフォゲンが、自然に生じたモルフォゲンのプロドメインから選択 されたプロドメインポリペプチドの少なくとも1つの溶解性増大フラグメントと 非共有結合的に複合体を形成するところの請求項1,6,7,8,15または2 0の方法。 24.前記モルフォゲンが前記フラグメントの対と複合体形成する請求項23の 方法。 25,前記モルフォゲンがモルフォゲン分泌宿主細胞の培養上清から得られる請 求項1,6,7,8,15,19または20の方法。 26.前記モルフォゲンがくも膜下に、心室内に、胞膜内にあるいは静脈内投与 される請求項1,6,7,8,15,19または20の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62044496A | 1996-03-22 | 1996-03-22 | |
US08/620,444 | 1996-03-22 | ||
PCT/US1997/004177 WO1997034626A1 (en) | 1996-03-22 | 1997-03-21 | Methods for enhancing functional recovery following central nervous system ischemia or trauma |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000506894A true JP2000506894A (ja) | 2000-06-06 |
JP4847634B2 JP4847634B2 (ja) | 2011-12-28 |
Family
ID=24485972
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9533791A Withdrawn JP2000507939A (ja) | 1996-03-22 | 1997-03-21 | 中枢神経系の虚血または外傷後のポリペプチド成長因子の投与 |
JP53358397A Expired - Fee Related JP4847634B2 (ja) | 1996-03-22 | 1997-03-21 | 中枢神経系の虚血または外傷の機能的回復を増大させる方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9533791A Withdrawn JP2000507939A (ja) | 1996-03-22 | 1997-03-21 | 中枢神経系の虚血または外傷後のポリペプチド成長因子の投与 |
Country Status (11)
Country | Link |
---|---|
US (4) | US6407060B1 (ja) |
EP (3) | EP0904093A4 (ja) |
JP (2) | JP2000507939A (ja) |
KR (1) | KR20000064752A (ja) |
CN (1) | CN1181885C (ja) |
AT (2) | ATE493141T1 (ja) |
AU (2) | AU725341B2 (ja) |
CA (2) | CA2249368A1 (ja) |
DE (2) | DE69723429T3 (ja) |
ES (1) | ES2201287T5 (ja) |
WO (2) | WO1997034618A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014185178A (ja) * | 2004-11-22 | 2014-10-02 | Royal College Of Surgeons In Ireland | アンジオゲニンおよびその変異体による治療 |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6077823A (en) * | 1991-03-11 | 2000-06-20 | Creative Biomolecules, Inc. | Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
DE69433530T2 (de) | 1993-05-12 | 2005-01-05 | Genetics Institute, LLC, Cambridge | Bmp-11 zusammensetzungen |
US6498142B1 (en) | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
AU5244998A (en) * | 1996-11-15 | 1998-06-03 | Creative Biomolecules, Inc. | Morphogen-induced regeneration of sense perceptory tissues |
ATE278414T1 (de) * | 1997-05-05 | 2004-10-15 | Curis Inc | Therapien zur behandlung von akutem nierenversagen |
EP2309261A1 (en) * | 1997-05-30 | 2011-04-13 | Stryker Corporation | Methods for evaluating tissue morphogenesis and morphogenic activity |
WO1999028341A2 (en) * | 1997-12-04 | 1999-06-10 | Creative Biomolecules, Inc. | Maintenance of smooth muscle integrity by morphogenic proteins |
US20030170213A1 (en) * | 1998-01-23 | 2003-09-11 | Marc F. Charette | Methods and compositions for enhancing cognitive function using morphogenic proteins |
US7147839B2 (en) | 1998-05-29 | 2006-12-12 | Curis, Inc. | Methods for evaluating tissue morphogenesis and activity |
DE19837230A1 (de) * | 1998-08-17 | 2000-03-09 | Jean Krutmann | Neurotrophin-4 zur Behandlung von Tumoren neuroektodermalen Ursprungs |
CN1753686A (zh) * | 1999-08-18 | 2006-03-29 | 综合医院公司 | 用于促进从中枢神经系统损伤中恢复的方法、组合物和试剂盒 |
US6749850B1 (en) | 1999-08-18 | 2004-06-15 | The General Hospital Corporation | Methods, compositions and kits for promoting recovery from damage to the central nervous system |
US7060676B2 (en) | 1999-12-20 | 2006-06-13 | Trustees Of Tufts College | T. cruzi-derived neurotrophic agents and methods of use therefor |
US6855690B2 (en) | 2000-06-01 | 2005-02-15 | Children's Medical Center Corporation | Methods and compositions for treating ocular disorders |
EP1289540B1 (en) | 2000-06-01 | 2012-03-07 | Children's Medical Center Corporation | Oncomodulin for treating neurological disorders |
TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
US7763769B2 (en) | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
WO2002098361A2 (en) * | 2001-06-01 | 2002-12-12 | Xcyte Therapies, Inc. | T cell induced tissue repair and regeneration |
US20060259014A1 (en) | 2002-05-22 | 2006-11-16 | Surgimark, Inc. | Aspirator sleeve and suction handle |
US20040229292A1 (en) * | 2002-11-26 | 2004-11-18 | Sebastiano Cavallaro | Use of FGF-18 in the diagnosis and treatment of memory disorders |
CN100558398C (zh) | 2002-11-26 | 2009-11-11 | 拜奥康有限公司 | 修饰的钠尿化合物、缀合物及其应用 |
JP2006524991A (ja) | 2003-05-08 | 2006-11-09 | エクサイト セラピーズ インコーポレーティッド | 抗原特異的t細胞の作製および単離の方法 |
JP4971149B2 (ja) | 2004-06-17 | 2012-07-11 | スラソス セラピューティックス インコーポレーテッド | Tdf関連化合物およびその類似体 |
AU2005258161B2 (en) * | 2004-06-21 | 2011-05-26 | The Board Of Trustees Of The Leland Stanford Junior University | Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder |
US20080108547A1 (en) * | 2004-07-20 | 2008-05-08 | Taylor Ii Larry Edmund | Protease Inhibitor |
EP1782821A4 (en) * | 2004-07-29 | 2009-11-11 | Anges Mg Inc | MEDICAMENT AND METHOD FOR IMPROVING BRAIN FUNCTION |
US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
DK2497780T3 (en) | 2005-09-20 | 2015-06-01 | Thrasos Innovation Inc | TDF-related compounds and analogs thereof |
JP5366554B2 (ja) | 2005-11-12 | 2013-12-11 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | うつを診断および処置するためのfgf2関連方法 |
AU2007234612B2 (en) * | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
PT2121142E (pt) * | 2007-01-25 | 2013-04-30 | Bioph Biotech Entw Pharm Gmbh | Utilização de gdf-5 para a melhoria ou conservação do aspeto dérmico |
US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
WO2009020744A1 (en) | 2007-08-07 | 2009-02-12 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations comprising gdf-5 in aqueous acidic solution |
CN102026619A (zh) * | 2008-04-14 | 2011-04-20 | 先进科技及再生医学有限责任公司 | 液体缓冲的gdf-5制剂 |
SG173632A1 (en) | 2009-02-12 | 2011-09-29 | Stryker Corp | Peripheral administration of proteins including tgf-beta superfamily members for systemic treatment of disorders and disease |
WO2010093941A2 (en) | 2009-02-12 | 2010-08-19 | Stryker Corporation | COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS |
JP5749659B2 (ja) | 2009-03-12 | 2015-07-15 | ハーゼ インベストメンツ ウーゲー | Bmpアンタゴニスト感受性が低下した骨形成タンパク質2(bmp2)変異体 |
US20110002897A1 (en) | 2009-06-11 | 2011-01-06 | Burnham Institute For Medical Research | Directed differentiation of stem cells |
US20110224410A1 (en) | 2009-09-17 | 2011-09-15 | Hile David | Buffers for Controlling the pH of Bone Morphogenetic Proteins |
CA2785038A1 (en) | 2009-12-22 | 2011-07-21 | Stryker Corporation | Bmp-7 variants with reduced immunogenicity |
CN101822815A (zh) * | 2010-04-29 | 2010-09-08 | 广东八加一医药有限公司 | 系列多肽小分子在制备防治缺血性脑血管疾病药物中的应用 |
US9688735B2 (en) | 2010-08-20 | 2017-06-27 | Wyeth Llc | Designer osteogenic proteins |
CN103079585B (zh) | 2010-08-20 | 2015-09-30 | 惠氏有限责任公司 | 经设计的成骨蛋白 |
EP2801377B1 (en) | 2011-03-04 | 2019-08-07 | The Regents of The University of California | Hydrogel comprising cells for local release of growth factors to mediate motor recovery after stroke |
KR101274930B1 (ko) * | 2011-06-03 | 2013-06-17 | 전남대학교산학협력단 | 골 형성 또는 혈관신생 촉진용 펩타이드 bfp 4 및 이의 용도 |
EP2734220A4 (en) * | 2011-07-19 | 2015-01-21 | Thrasos Innovation Inc | ANTIFIBROTIC PEPTIDES AND THEIR USE IN METHODS OF TREATING FIBROSIS-CHARACTERIZED DISEASES AND SUFFERING |
EP2784083A1 (en) | 2013-03-28 | 2014-10-01 | Charité - Universitätsmedizin Berlin | Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity |
CA2911514A1 (en) | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
AU2016218977C1 (en) | 2015-02-13 | 2023-03-23 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
IL308824A (en) | 2016-08-17 | 2024-01-01 | Factor Bioscience Inc | Nucleic acid products and methods of their administration |
MX2021000157A (es) * | 2018-07-03 | 2021-12-10 | Venturis Therapeutics Inc | Composiciones y métodos para tratar el derrame cerebral. |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4440860A (en) | 1980-01-18 | 1984-04-03 | The Children's Medical Center Corporation | Stimulating cell growth |
US4378347A (en) * | 1980-06-30 | 1983-03-29 | Franco Wayne P | Composition for treating the heart for myocardial infarction |
US4296100A (en) | 1980-06-30 | 1981-10-20 | Franco Wayne P | Method of treating the heart for myocardial infarction |
DE3110560A1 (de) | 1981-03-18 | 1982-10-14 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben" |
EP0105014B1 (en) | 1982-09-24 | 1992-05-20 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Repair of tissue in animals |
US4971952A (en) | 1986-03-06 | 1990-11-20 | Collagen Corporation | Method of treating inflammation with cartilage inducing factor |
US4806523A (en) | 1985-08-06 | 1989-02-21 | Collagen Corporation | Method of treating inflammation |
US4994559A (en) | 1985-12-17 | 1991-02-19 | Synergen, Inc. | Human basic fibroblast growth factor |
IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Factors that soak bone formation |
US4801575A (en) | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4861757A (en) | 1986-11-14 | 1989-08-29 | Institute Of Molecular Biology | Wound healing and bone regeneration using PDGF and IGF-I |
EP0269408A3 (en) | 1986-11-26 | 1989-08-30 | Genentech, Inc. | Tgf-beta in the treatment of inflammatory disorders |
US4797277A (en) | 1987-09-22 | 1989-01-10 | Pharmacia Ab | Method for reperfusion therapy |
US5011691A (en) | 1988-08-15 | 1991-04-30 | Stryker Corporation | Osteogenic devices |
US5108753A (en) | 1988-04-08 | 1992-04-28 | Creative Biomolecules | Osteogenic devices |
JPH0262829A (ja) | 1988-05-18 | 1990-03-02 | Nippon Kayaku Co Ltd | 虚血に基づく傷害の予防及び治療剤 |
US4983581A (en) | 1988-05-20 | 1991-01-08 | Institute Of Molecular Biology, Inc. | Wound healing composition of IGF-I and TGF-β |
HU201095B (en) | 1988-06-14 | 1990-09-28 | Richter Gedeon Vegyeszet | New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions |
JPH03505669A (ja) | 1988-07-08 | 1991-12-12 | ユニバーシテイ・カレツジ・ロンドン | バイオアツセイにおける改良 |
AU4056089A (en) | 1988-07-20 | 1990-02-19 | Amgen, Inc. | Method of treating inflammatory disorders by reducing phagocyte activation |
US5057494A (en) | 1988-08-03 | 1991-10-15 | Ethicon, Inc. | Method for preventing tissue damage after an ischemic episode |
US5106626A (en) | 1988-10-11 | 1992-04-21 | International Genetic Engineering, Inc. | Osteogenic factors |
US5135915A (en) | 1988-10-14 | 1992-08-04 | Genentech, Inc. | Method for the treatment of grafts prior to transplantation using TGF-.beta. |
US5011914A (en) | 1989-01-05 | 1991-04-30 | Collins Franklin D | Purified ciliary neurotrophic factor |
US5002965A (en) | 1989-05-09 | 1991-03-26 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Use of ginkgolides to prevent reperfusion injury in organ transplantation |
US5118791A (en) | 1989-05-25 | 1992-06-02 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
IL97365A0 (en) * | 1991-02-27 | 1992-05-25 | Yeda Res & Dev | Pharmaceutical compositions comprising a lymphokine |
US5158934A (en) | 1989-09-01 | 1992-10-27 | Genentech, Inc. | Method of inducing bone growth using TGF-β |
CA2042577A1 (en) | 1989-10-17 | 1991-04-18 | Hermann Oppermann | Osteogenic devices |
US5108989A (en) | 1990-04-04 | 1992-04-28 | Genentech, Inc. | Method of predisposing mammals to accelerated tissue repair |
AU666291B2 (en) | 1990-06-15 | 1996-02-08 | Carnegie Institution Of Washington | Gdf-1 |
DE69133338T2 (de) | 1990-09-26 | 2004-04-15 | Genetics Institute, LLC, Cambridge | Bmp-5-derivate |
CA2094027C (en) | 1990-10-18 | 2001-12-25 | Hermann Oppermann | Osteogenic peptides |
CA2096441A1 (en) | 1990-11-16 | 1992-05-17 | Celtrix Pharmaceuticals, Inc. | Heterodimer of b-type transforming growth factors 2 and 3 |
JP3604688B2 (ja) | 1990-11-27 | 2004-12-22 | ジ・アメリカン・ナショナル・レッド・クロス | 加速された傷の治癒を促進する組織シーラントおよび成長因子含有組成物 |
CA2071912C (en) | 1990-11-30 | 2002-10-15 | Hanne Bentz | Use of a bone morphogenetic protein in synergistic combination with tgf-beta for bone repair |
WO1992015323A1 (en) * | 1991-03-11 | 1992-09-17 | Creative Biomolecules, Inc. | Protein-induced morphogenesis |
US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
AU654724B2 (en) | 1991-05-10 | 1994-11-17 | Salk Institute For Biological Studies, The | Cloning and recombinant production of receptor(s) of the activin/TGF-beta superfamily |
AU662155B2 (en) | 1991-05-10 | 1995-08-24 | Celtrix Pharmaceuticals, Inc. | Targeted delivery of bone growth factors |
KR0145278B1 (ko) | 1991-06-21 | 1998-07-15 | 브루스 엠. 에이센 | 골형성원 단백질 약제 |
ATE175441T1 (de) | 1991-06-25 | 1999-01-15 | Genetics Inst | Bmp-9 zusammensetzungen |
EP0601129B1 (en) | 1991-08-30 | 2000-11-15 | Creative Biomolecules, Inc. | Morphogenic protein screening method |
CA2116559C (en) | 1991-08-30 | 2005-05-10 | Thangavel Kuberasampath | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
CA2116562C (en) * | 1991-08-30 | 1999-04-13 | Thangavel Kuberasampath | Morphogen-induced modulation of inflammatory response |
DE69233022T2 (de) | 1991-11-04 | 2004-02-12 | Genetics Institute, LLC, Cambridge | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung |
US5733871A (en) * | 1991-11-08 | 1998-03-31 | The General Hospital Corporation | Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration |
ES2133333T3 (es) * | 1991-11-22 | 1999-09-16 | Genentech Inc | Tgf-beta para mejorar la recuperacion de las neuronas. |
DE19525416A1 (de) † | 1995-07-12 | 1997-01-16 | Bioph Biotech Entw Pharm Gmbh | Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems |
ES2201059T5 (es) * | 1992-07-31 | 2007-11-01 | Curis, Inc. | Regeneracion y reparacion de nervios inducida por morfogenos. |
ES2061380B1 (es) * | 1992-11-23 | 1995-07-01 | Boehringer Ingelheim Espana | Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores. |
JPH09501932A (ja) † | 1993-08-26 | 1997-02-25 | ジェネティックス・インスティテュート・インコーポレイテッド | ヒト・骨形態形成蛋白を用いる神経再生 |
WO1995006656A1 (en) | 1993-09-03 | 1995-03-09 | The Regents Of The University Of California | Neural tissue affecting factor and compositions |
ATE355369T1 (de) | 1993-10-14 | 2006-03-15 | Harvard College | Verfahren zur induzierung und zur erhaltung neuronalen zellen |
WO1995024474A1 (en) | 1994-03-10 | 1995-09-14 | Human Genome Sciences, Inc. | Bone morphogenic protein-10 |
AU5244998A (en) * | 1996-11-15 | 1998-06-03 | Creative Biomolecules, Inc. | Morphogen-induced regeneration of sense perceptory tissues |
-
1997
- 1997-03-21 KR KR1019980707507A patent/KR20000064752A/ko not_active Application Discontinuation
- 1997-03-21 DE DE69723429T patent/DE69723429T3/de not_active Expired - Lifetime
- 1997-03-21 CN CNB97194749XA patent/CN1181885C/zh not_active Expired - Fee Related
- 1997-03-21 WO PCT/US1997/005071 patent/WO1997034618A1/en not_active Application Discontinuation
- 1997-03-21 CA CA002249368A patent/CA2249368A1/en not_active Abandoned
- 1997-03-21 AU AU25823/97A patent/AU725341B2/en not_active Ceased
- 1997-03-21 WO PCT/US1997/004177 patent/WO1997034626A1/en active IP Right Grant
- 1997-03-21 AT AT03010945T patent/ATE493141T1/de not_active IP Right Cessation
- 1997-03-21 US US08/828,281 patent/US6407060B1/en not_active Expired - Lifetime
- 1997-03-21 DE DE69740089T patent/DE69740089D1/de not_active Expired - Lifetime
- 1997-03-21 JP JP9533791A patent/JP2000507939A/ja not_active Withdrawn
- 1997-03-21 EP EP97917091A patent/EP0904093A4/en not_active Withdrawn
- 1997-03-21 JP JP53358397A patent/JP4847634B2/ja not_active Expired - Fee Related
- 1997-03-21 EP EP03010945A patent/EP1364655B1/en not_active Expired - Lifetime
- 1997-03-21 ES ES97917532T patent/ES2201287T5/es not_active Expired - Lifetime
- 1997-03-21 US US08/822,455 patent/US6214796B1/en not_active Expired - Fee Related
- 1997-03-21 AU AU25529/97A patent/AU734312B2/en not_active Ceased
- 1997-03-21 EP EP97917532A patent/EP0894004B2/en not_active Expired - Lifetime
- 1997-03-21 AT AT97917532T patent/ATE244574T1/de not_active IP Right Cessation
- 1997-03-21 CA CA2249596A patent/CA2249596C/en not_active Expired - Fee Related
-
2001
- 2001-04-10 US US09/833,096 patent/US20010039261A1/en not_active Abandoned
-
2002
- 2002-02-01 US US10/062,370 patent/US20030022830A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014185178A (ja) * | 2004-11-22 | 2014-10-02 | Royal College Of Surgeons In Ireland | アンジオゲニンおよびその変異体による治療 |
Also Published As
Publication number | Publication date |
---|---|
WO1997034626A1 (en) | 1997-09-25 |
EP1364655A1 (en) | 2003-11-26 |
ATE244574T1 (de) | 2003-07-15 |
CN1219133A (zh) | 1999-06-09 |
WO1997034618A1 (en) | 1997-09-25 |
DE69723429D1 (de) | 2003-08-14 |
EP0894004A1 (en) | 1999-02-03 |
JP4847634B2 (ja) | 2011-12-28 |
EP0904093A1 (en) | 1999-03-31 |
DE69723429T2 (de) | 2004-04-22 |
EP1364655B1 (en) | 2010-12-29 |
AU2582397A (en) | 1997-10-10 |
AU725341B2 (en) | 2000-10-12 |
EP0904093A4 (en) | 2004-11-17 |
KR20000064752A (ko) | 2000-11-06 |
DE69740089D1 (de) | 2011-02-10 |
ATE493141T1 (de) | 2011-01-15 |
JP2000507939A (ja) | 2000-06-27 |
CA2249368A1 (en) | 1997-09-25 |
EP0894004B2 (en) | 2007-02-21 |
US20030022830A1 (en) | 2003-01-30 |
DE69723429T3 (de) | 2007-09-20 |
AU734312B2 (en) | 2001-06-07 |
EP0894004B1 (en) | 2003-07-09 |
US20010039261A1 (en) | 2001-11-08 |
ES2201287T5 (es) | 2007-10-16 |
CN1181885C (zh) | 2004-12-29 |
US6407060B1 (en) | 2002-06-18 |
CA2249596C (en) | 2011-11-08 |
ES2201287T3 (es) | 2004-03-16 |
AU2552997A (en) | 1997-10-10 |
US6214796B1 (en) | 2001-04-10 |
CA2249596A1 (en) | 1997-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4847634B2 (ja) | 中枢神経系の虚血または外傷の機能的回復を増大させる方法 | |
Hamilton et al. | Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin | |
JP4766722B2 (ja) | 慢性腎不全の形態形成因子処置 | |
US7119066B2 (en) | Modified ciliary neurotrophic factor (CNTF) | |
EP1137401B1 (en) | Administration of neurotrophic agents to the central nervous system | |
JP5346657B2 (ja) | 組織形態形成および活性を評価するための方法 | |
US6723698B2 (en) | Methods and compositions for the treatment of motor neuron injury and neuropathy | |
US20070191276A1 (en) | Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors | |
US6506729B1 (en) | Methods and compositions for the treatment and prevention of Parkinson's disease | |
JP2002505851A (ja) | 骨形態形成タンパク(bmp)−17およびbmp−18の組成物 | |
US20020032153A1 (en) | Methods and compositions for the treatment and prevention of erectile dysfunction | |
EP2352750B1 (en) | Buffers for controlling the ph of bone morphogenetic proteins | |
EP1398039A1 (en) | Morphogenic proteins for enhancing cognitive function | |
US20110224138A1 (en) | Methods for treating pain induced by injuries and diseases of an articular joint | |
AU773990B2 (en) | Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors | |
EP1100523A1 (en) | Treatment of central nervous system ischemia or trauma with epidermal growth factor-like polypeptides | |
JPH08283174A (ja) | 脊髄損傷後の神経障害に対する治療剤 | |
WO2022204331A1 (en) | Compositions comprising branched kgf-2 derived peptides and methods for use in ocular treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060328 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060621 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060807 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060830 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070806 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070904 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071015 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20071016 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071029 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20071220 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20080424 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20100204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100317 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110608 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20110607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110707 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110809 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111014 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141021 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |